Related Experiment Video
Updated: Mar 31, 2026
Isolation and Flow Cytometric Analysis of Glioma-infiltrating Peripheral Blood Mononuclear Cells
Published on: November 28, 2015
Immunosuppressive mechanisms in glioblastoma
Edjah K Nduom1, Michael Weller1, Amy B Heimberger1
1Department of Neurosurgery, The University of Texas M.D. Anderson Cancer Center, Houston, Texas (E.K.N., A.B.H.); Department of Neurology, University Hospital Zurich, Zurich, Switzerland (M.W.).
Abstract:
Despite maximal surgical and medical therapy, the treatment of glioblastoma remains a seriously vexing problem, with median survival well under 2 years and few long-term survivors. Targeted therapy has yet to produce significant advances in treatment of these lesions in spite of advanced molecular characterization of glioblastoma and glioblastoma cancer stem cells. Recently, immunotherapy has emerged as a promising mode for some of the hardest to treat tumors, including metastatic melanoma. Although immunotherapy has been evaluated in glioblastoma in the past with limited success, better understanding of the failures of these therapies could lead to more successful treatments in the future. Furthermore, there is a persistent challenge for the use of immune therapy to treat glioblastoma secondary to the existence of redundant mechanisms of tumor-mediated immune suppression. Here we will address these mechanisms of immunosuppression in glioblastoma and therapeutic approaches.
Insights
Glioblastoma treatment remains challenging, with limited survival rates. This review explores glioblastoma
Area of Science:
- Neuro-oncology
- Immunology
- Cancer Biology
Background:
- Glioblastoma (GBM) presents significant therapeutic challenges, with poor median survival despite aggressive treatments.
- Targeted therapies have shown limited efficacy against GBM, even with advanced molecular profiling.
- Immunotherapy offers promise for difficult-to-treat cancers, but past GBM trials yielded modest results.
Purpose of the Study:
- To review the mechanisms of immune suppression in glioblastoma.
- To discuss potential immunotherapy strategies for glioblastoma.
Main Methods:
- Literature review of glioblastoma immunology and immunotherapy.
- Analysis of tumor-mediated immune suppression pathways in glioblastoma.
Main Results:
- Glioblastoma employs multiple redundant mechanisms to suppress the immune response.
- Past immunotherapy efforts in glioblastoma have been hampered by these suppressive factors.
Conclusions:
- Understanding glioblastoma's immunosuppressive microenvironment is crucial for developing effective immunotherapies.
- Novel therapeutic approaches targeting immune suppression are needed to improve glioblastoma patient outcomes.
